AxoGen, Inc. to Attend American Association of Oral and Maxillofacial Surgeons (AAOMS) 97th Annual Meeting

Share Article

Company to Exhibit Portfolio of Nerve Repair Products at Booth 244

AxoGen Logo

We are pleased to be able to support the AAOMS with educational materials both during the exhibit and other activities throughout the conference.

AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced its participation in the 2015 American Association of Oral and Maxillofacial Surgeons (AAOMS) 97th Annual Meeting taking place at Walter E. Washington Convention Center in Washington D. C. AxoGen will exhibit its proprietary portfolio of peripheral nerve repair products including Avance® Nerve Graft, AxoGuard® Nerve Connector and AxoGuard® Nerve Protector, at Booth #244 from October 1-3, 2015.

“Trigeminal nerve injuries can have a devastating impact on patient quality of life. Patients with trigeminal nerve injuries may suffer from pain, discomfort and loss of sensation in the mouth,” says Erick DeVinney, AxoGen’s Vice President of Clinical and Translational Sciences. “AxoGen is committed to raising awareness on the repair options for these nerve injuries and to supporting educational efforts for surgeons actively treating or referring patients with nerve injuries. We are pleased to be able to support the AAOMS with educational materials both during the exhibit and other activities throughout the conference.”

About the Trigeminal Nerve

The trigeminal nerve is a peripheral nerve responsible for sensation in the mouth and taste. A common cause of damage to the trigeminal nerve is the extraction of third molars (wisdom teeth) and injury caused by the placement of dental implants. The trigeminal nerve can also be injured due to certain jaw alignment and tumor removal surgeries as well as by trauma to the face.

About AxoGen, Inc.

AxoGen (NASDAQ: AXGN) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen’s portfolio of regenerative medicine products is available in the United States, Canada and several other countries and includes Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.

Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed worldwide exclusively by AxoGen. AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation.

For more information about AxoGen or to sign up for our news alerts, please visit

Cautionary Statements Concerning Forward-Looking Statements

This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts", "continue", "may", "should", "will" variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our growth, our 2015 revenue estimate, product development, product potential, financial performance, sales growth, product adoption, market awareness of our products, data validation, our visibility at and sponsorship of conferences and educational events. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.


AxoGen, Inc.
Customer Care
888.AXOGEN1 (888.296.4361)

EVC Group
Michael Polyviou/Doug Sherk – Investor Relations            
mpolyviou(at)evcgroup(dot)com; dsherk(at)evcgroup(dot)com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michael Polyviou/Doug Sherk - Investor Relations
EVC Group
+1 212.850.6020
Email >
Visit website